当前位置: X-MOL 学术Mol. Genet. Metab. Rep. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinical outcomes in an adult patient with mannose phosphate isomerase-congenital disorder of glycosylation who discontinued mannose therapy.
Molecular Genetics and Metabolism Reports ( IF 1.8 ) Pub Date : 2020-09-07 , DOI: 10.1016/j.ymgmr.2020.100646
Kinza Noman 1 , Christian J Hendriksz 2 , Graham Radcliffe 3 , Federico Roncaroli 4 , Sulleman Moreea 5 , Afifah Hussain 6 , Karolina M Stepien 7
Affiliation  

The mannose phosphate isomerase-congenital disorder of glycosylation (MPI-CDG) is caused by phosphomannose isomerase deficiency. Clinical features include hyperinsulinaemic hypoglycaemia, protein losing enteropathy, hepatomegaly and hepatic fibrosis, digestive symptoms and coagulation abnormalities. The condition is treated with mannose supplementation. Long-term outcomes in adults are not well described. We present a case of an adult female patient who discontinued mannose therapy in her adolescence. In adulthood she developed gastrointestinal problems, chronic anaemia and osteophytes in her knees.



中文翻译:

甘露糖磷酸异构酶-先天性糖基化疾病成年患者中止甘露糖治疗的临床结果。

甘露糖磷酸异构酶-先天性糖基化疾病(MPI-CDG)是由磷酸甘露糖异构酶缺乏引起的。临床特征包括高胰岛素血症性低血糖,蛋白质丢失性肠病,肝肿大和肝纤维化,消化系统症状和凝血异常。该病用甘露糖补充剂治疗。成人的长期结局没有得到很好的描述。我们介绍了一例成年女性患者,该患者在青春期停止甘露糖治疗。成年后,她的膝盖出现了胃肠道问题,慢性贫血和骨赘。

更新日期:2020-09-07
down
wechat
bug